Ellagic acid protects against cisplatin-induced nephrotoxicity in rats: A dose-dependent study

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 3, 2013, Pages 299-310

  Al Kharusi, N ^a   Babiker, H A ^a   Al Salam, S ^b   Waly, M I ^a   Nemmar, A ^b   Al Lawati, I ^a   Yasin, J ^b   Beegam, S ^a   Ali, B H ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cisplatin; Ellagic acid; Nephrotoxicity; Rats

Indexed keywords

CISPLATIN; CLUSTERIN; ELLAGIC ACID; GLUTATHIONE; KIDNEY INJURY MOLECULE 1; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; FEMALE; FLUID INTAKE; HISTOPATHOLOGY; KIDNEY CORTEX NECROSIS; KIDNEY FUNCTION; KIDNEY MASS; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RAT; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL ADHESION MOLECULES; CISPLATIN; CLUSTERIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELLAGIC ACID; FEMALE; KIDNEY DISEASES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84878599561     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. MILLER RP, TADAGAVADI RK, RAMESH G, REEVES WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2010; 2: 2490-2518.
2. ALI BH, AL MOUNDHRI MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006; 44: 1173-1183.
3. HANIGAN MH, DEVARAJAN P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 2003; 1: 47-61.
4. PABLA N, MURPHY RF, LIU K, DONG Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296: F505-511.
5. YONEZAWA A, INUI K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 2011; 81: 563-568.
6. SANTOS NA, CATAO CS, MARTINS NM, CURTI C, BIANCHI ML, SANTOS AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 2007; 81: 495-504.
7. CHIRINO YI, PEDRAZA-CHAVERRI J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009; 61: 223-242.
8. DEVIPRIYA N, SRINIVASAN M, SUDHEER AR, MENON VP. Effect of ellagic acid, a natural polyphenol, on alcohol- induced prooxidant and antioxidant imbalance: a drug dose dependent study. Singapore Med J 2007; 48: 311-318.
9. KANNAN MM, QUINE SD. Ellagic acid ameliorates isoproterenol induced oxidative stress: Evidence from electrocardiological, biochemical and histological study. Eur J Pharmacol 2011; 659: 45-52.
10. UMESALMA S, SUDHANDIRAN G. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur J Pharmacol 2011; 660: 249-258.
11. ROMERT L, JANSSON T, CURVALL M, JENSSEN D. Screening for agents inhibiting the mutagenicity of extracts and constituents of tobacco products. Mutat Res 1994; 322: 97-110.
12. KASSIM M, ACHOUI M, MUSTAFA MR, MOHD MA, YUSOFF KM. Ellagic acid, phenolic acids, and flavonoids in Malaysian honey extracts demonstrate in vitro anti-inflammatory activity. Nutr Res 2010; 30: 650-659.
13. ROSILLO MA, SANCHEZ-HIDALGO M, CARDENO A, DE LA LASTRA CA. Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's disease. Biochem Pharmacol 2011; 82: 737-745.
14. TURK G, CERIBASI AO, SAHNA E, ATESSAHIN A. Lycopene and ellagic acid prevent testicular apoptosis induced by cisplatin. Phytomedicine 2011; 18: 356-361.
15. ATESSAHIN A, CERIBASI AO, YUCE A, BULMUS O, CIKIM G. Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 2007; 100: 121-126.
16. ALI BH, AL-MOUNDHRI M, TAGELDIN M, AL HUSSEINI IS, MANSOUR MA, NEMMAR A, TANIRA MO. Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol 2008; 46: 3355-3359.
17. BATISTA BL, GROTTO D, RODRIGUES JL, SOUZA VC, BARBOSA F, JR. Determination of trace elements in biological samples by inductively coupled plasma mass spectrometry with tetramethylammonium hydroxide solubilization at room temperature. Anal Chim Acta 2009; 646: 23-29.
18. MOHAN IK, KHAN M, SHOBHA JC, NAIDU MU, PRAYAG A, KUPPUSAMY P, KUTALA VK. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats. Cancer Chemother Pharmacol 2006; 58: 802-808.
19. VIELHAUER V, STAVRAKIS G, MAYADAS TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005; 115: 1199-1209.
20. ER TK. Effect of sample volume for the measurement of osmolality by using the Advanced 3250 osmometer. Am J Emerg Med 2008; 26: 1060-1061.
21. MILLER NJ, RICE-EVANS C, DAVIES MJ, GOPINATHAN V, MILNER A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 1993; 84: 407-412.
22. GUNTHERBERG H, ROST J. The true oxidized glutathione content of red blood cells obtained by new enzymic and paper chromatographic methods. Anal Biochem 1966; 15: 205-210.
23. GRIFFITH OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980; 106: 207-212.
24. BRADFORD MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
25. VERA G, CHIARLONE A, MARTIN MI, ABALO R. Altered feeding behaviour induced by long-term cisplatin in rats. Auton Neurosci 2006; 126-127: 81-92.
26. SAAD SY, NAJJAR TA, AL-SOHAIBANI MO. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. Pharmacol Res 2000; 42: 81-86.
27. HAASE M, MERTENS PR. Urinary biomarkers-silver bullets to faster drug development and nephron protection. Nephrol Dial Transplant 2010; 25: 3167-3169.
28. SUNG MJ, KIM DH, JUNG YJ, KANG KP, LEE AS, LEE S, KIM W, DAVAATSEREN M, HWANG JT, KIM HJ, KIM MS, KWON DY, PARK SK. Genistein protects the kidney from cisplatin-induced injury. Kidney Int 2008; 74: 1538-1547.
29. AN Y, XIN H, YAN W, ZHOU X. Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice. Exp Toxicol Pathol 2011; 63: 215-219.
30. AHMAD ST, SULTANA S. Tannic acid mitigates cisplatin-induced nephrotoxicity in mice. Human Exp Toxicol 2012; 31: 145-156.
31. WONG NL, WALKER VR, WONG EF, SUTTON RA. Mechanism of polyuria after cisplatin therapy. Nephron 1993; 65: 623-627.
32. ABDELRAHMAN AM, AL SALAM S, ALMAHRUQI AS, AL HUSSENI IS, MANSOUR MA, ALI BH. N-acetylcysteine improves renal hemodynamics in rats with cisplatin-induced nephrotoxicity. J Appli Toxicol 2010; 30: 15-21.
33. BOUAYED J, BOHN T. Exogenous antioxidants-Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev 2010; 3: 228-237.
34. OZER JS, DIETERLE F, TROTH S, PERENTES E, CORDIER A, VERDES P, STAEDTLER F, MAHL A, GRENET O, ROTH DR, WAHL D, LEGAY F, HOLDER D, ERDOS Z, VLASAKOVA K, JIN H, YU Y, MUNIAPPA N, FOREST T, CLOUSE HK, REYNOLDS S, BAILEY WJ, THUDIUM DT, TOPPER MJ, SKOPEK TR, SINA JF, GLAAB WE, VONDERSCHER J, MAURER G, CHIBOUT SD, SISTARE FD, GERHOLD DL. A PANel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010; 28: 486-494.
35. ROSENBERG ME, SILKENSEN J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27: 633-645.
36. DIETERLE F, PERENTES E, CORDIER A, ROTH DR, VERDES P, GRENET O, PANTANO S, MOULIN P, WAHL D, MAHL A, END P, STAEDTLER F, LEGAY F, CARL K, LAURIE D, CHIBOUT SD, VONDERSCHER J, MAURER G. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect druginduced kidney injury. Nat Biotechnol 2010; 28: 463-469.
37. VAIDYA VS, OZER JS, DIETERLE F, COLLINGS FB, RAMIREZ V, TROTH S, MUNIAPPA N, THUDIUM D, GERHOLD D, HOLDER DJ, BOBADILLA NA, MARRER E, PERENTES E, CORDIER A, VONDERSCHER J, MAURER G, GOERING PL, SISTARE FD, BONVENTRE JV. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010; 28: 478-485.
38. MALYSZKO J, KOC-ZORAWSKA E, MALYSZKO JS, MYSLIWIEC M. Kidney injury molecule-1 correlates with kidney function in renal allograft recipients. Transplantat Proc 2010; 42: 3957-3959.
39. HARPUR E, ENNULAT D, HOFFMAN D, BETTON G, GAUTIER JC, RIEFKE B, BOUNOUS D, SCHUSTER K, BEUSHAUSEN S, GUFFROY M, SHAW M, LOCK E, PETTIT S; HESI COMMITTEE ON BIOMARKERS OF NEPHROTOXICITY. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol Sci 2011; 122: 235-252.